Obesity
Not recruitingStudy to Evaluate the Effectiveness of Survodutide in Reducing Liver Fat and Weight in Patients with Obesity or Overweight and Non-Alcoholic Steatohepatitis (NASH)
Study to Evaluate the Effectiveness of Survodutide in Reducing Liver Fat and Weight in Patients with Obesity or Overweight and Non-Alcoholic Steatohepatitis (NASH)
- Disease:Obesity
- Substances:BI 456906SURVODUTIDE
Germany- Participants:18–64 years · 65+ years
- Substances:BI 456906
- Sponsor:Boehringer Ingelheim International GmbH














